MRx0518
- Generic Name
- MRx0518
- Drug Type
- Biotech
Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma
Phase 2
Withdrawn
- Conditions
- Urothelial Carcinoma
- Interventions
- Biological: Avelumab 20 mg/mL Intravenous Solution (IV)
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- 4D pharma plc
- Registration Number
- NCT05107427
- Locations
- 🇺🇸
University of California Irvine, Irvine, California, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
Phase 1
Terminated
- Conditions
- Pancreatic Cancer
- Interventions
- Radiation: Hypofractionated Preoperative Radiation
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 13
- Registration Number
- NCT04193904
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
Phase 1
- Conditions
- Ovarian CancerProstate CancerUrethral CancerBladder CancerRenal CancerHead and Neck CancerBreast CancerUterine CancerMelanomaLung Cancer
- Interventions
- Drug: MRx0518/placebo Capsules
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 120
- Registration Number
- NCT03934827
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
Phase 1
Terminated
- Conditions
- OncologySolid TumorRenal Cell CarcinomaBladder CancerNon Small Cell Lung CancerMelanoma
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- 4D pharma plc
- Target Recruit Count
- 63
- Registration Number
- NCT03637803
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Houston Methodist Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath